Literature DB >> 15785866

Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome.

K R Kessler1, N Hamscho, B Morales, C Menzel, F Barrero, F Vives, S Gispert, G Auburger.   

Abstract

A G309D mutation in the PINK1 gene in a consanguineous Spanish kindred with seven siblings, three of whom are clinically affected, has recently been shown to be a cause of the PARK6 form of autosomal-recessive Parkinson's syndrome. In this family, we studied pre- and postsynaptic dopaminergic function using 123I-FP-CIT- and 123I-iodobenzamide-SPECT to determine binding to the presynaptic dopamine transporter (DAT) and postsynaptic D2 receptors respectively. All three PARK6 patients showed reduced striatal DAT binding with posterior preponderance similar to sporadic idiopathic PD, but only one patient showed significant striatal asymmetry. In two of the siblings, DAT binding was markedly increased. IBZM-SPECT was normal in both patients and sibs. Our findings indicate that 123I-FP-CIT-SPECT shows similar DAT binding in PARK6 patients compared to idiopathic Parkinson's disease. The increased DAT binding in heterozygous PARK6 carriers may be a new very early preclinical finding, but its significance is still unclear.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15785866     DOI: 10.1007/s00702-005-0281-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  25 in total

1.  Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients.

Authors:  M Plotkin; H Amthauer; S Klaffke; A Kühn; L Lüdemann; G Arnold; K-D Wernecke; A Kupsch; R Felix; S Venz
Journal:  J Neural Transm (Vienna)       Date:  2004-09-14       Impact factor: 3.575

2.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123 I]-FP-CIT SPECT imaging: The [123 I]-FP-CIT study group.

Authors:  Hani T S Benamer; Jim Patterson; Donald G Grosset; J Booij; K de Bruin; E van Royen; J D Speelman; M H I M Horstink; H J W A Sips; R A Dierckx; J Versijpt; D Decoo; C Van Der Linden; D M Hadley; M Doder; A J Lees; D C Costa; S Gacinovic; W H Oertel; O Pogarell; H Hoeffken; K Joseph; K Tatsch; J Schwarz; V Ries
Journal:  Mov Disord       Date:  2000-05       Impact factor: 10.338

3.  Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study.

Authors:  P Piccini; P K Morrish; N Turjanski; G V Sawle; D J Burn; R A Weeks; M H Mark; D M Maraganore; A J Lees; D J Brooks
Journal:  Ann Neurol       Date:  1997-02       Impact factor: 10.422

4.  Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes.

Authors:  R Benecke; P Strümper; H Weiss
Journal:  Brain       Date:  1993-12       Impact factor: 13.501

Review 5.  Mitochondria, oxidative damage, and inflammation in Parkinson's disease.

Authors:  M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2003-06       Impact factor: 5.691

6.  Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette's disorder.

Authors:  Keun-Ah Cheon; Young-Hoon Ryu; Kee Namkoong; Chan-Hyung Kim; Jae-Jin Kim; Jong Doo Lee
Journal:  Psychiatry Res       Date:  2004-01-15       Impact factor: 3.222

7.  Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder.

Authors:  Keun-Ah Cheon; Young Hoon Ryu; Young-Kee Kim; Kee Namkoong; Chan-Hyung Kim; Jong Doo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-11-29       Impact factor: 9.236

Review 8.  Monoamine transporters: from genes to behavior.

Authors:  Raul R Gainetdinov; Marc G Caron
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-09-17       Impact factor: 13.820

9.  123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.

Authors:  J Schwarz; K Tatsch; G Arnold; M Ott; C Trenkwalder; C M Kirsch; W H Oertel
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

10.  Hereditary early-onset Parkinson's disease caused by mutations in PINK1.

Authors:  Enza Maria Valente; Patrick M Abou-Sleiman; Viviana Caputo; Miratul M K Muqit; Kirsten Harvey; Suzana Gispert; Zeeshan Ali; Domenico Del Turco; Anna Rita Bentivoglio; Daniel G Healy; Alberto Albanese; Robert Nussbaum; Rafael González-Maldonado; Thomas Deller; Sergio Salvi; Pietro Cortelli; William P Gilks; David S Latchman; Robert J Harvey; Bruno Dallapiccola; Georg Auburger; Nicholas W Wood
Journal:  Science       Date:  2004-04-15       Impact factor: 47.728

View more
  16 in total

1.  Subthalamic lesion or levodopa treatment rescues giant GABAergic currents of PINK1-deficient striatum.

Authors:  Nathalie Dehorter; Natalia Lozovaya; B Julius Mdzomba; François J Michel; Catherine Lopez; Vera Tsintsadze; Timur Tsintsadze; Michael Klinkenberg; Suzanna Gispert; Georg Auburger; Constance Hammond
Journal:  J Neurosci       Date:  2012-12-12       Impact factor: 6.167

2.  A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2.

Authors:  Hitoshi Murata; Masakiyo Sakaguchi; Yu Jin; Yoshihiko Sakaguchi; Jun-ichiro Futami; Hidenori Yamada; Ken Kataoka; Nam-ho Huh
Journal:  J Biol Chem       Date:  2010-12-21       Impact factor: 5.157

3.  Regulation of dopamine presynaptic markers and receptors in the striatum of DJ-1 and Pink1 knockout rats.

Authors:  Jianjun Sun; Evguenia Kouranova; Xiaoxia Cui; Robert H Mach; Jinbin Xu
Journal:  Neurosci Lett       Date:  2013-10-22       Impact factor: 3.046

Review 4.  [Imaging of genetic aspects of Parkinson's disease].

Authors:  N Brüggemann; J Vegt; C Klein; H R Siebner
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

5.  Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin.

Authors:  Nicole Exner; Bettina Treske; Dominik Paquet; Kira Holmström; Carola Schiesling; Suzana Gispert; Iria Carballo-Carbajal; Daniela Berg; Hans-Hermann Hoepken; Thomas Gasser; Rejko Krüger; Konstanze F Winklhofer; Frank Vogel; Andreas S Reichert; Georg Auburger; Philipp J Kahle; Bettina Schmid; Christian Haass
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

Review 6.  The mitochondrial kinase PINK1, stress response and Parkinson's disease.

Authors:  Marina Jendrach; Suzana Gispert; Filomena Ricciardi; Michael Klinkenberg; Rudolf Schemm; Georg Auburger
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

7.  PINK1 mutation in Taiwanese early-onset parkinsonism : clinical, genetic, and dopamine transporter studies.

Authors:  Yi-Hsin Weng; Yah-Huei Wu Chou; Wen-Shiang Wu; Kun-Ju Lin; Hsiu-Chen Chang; Tzu-Chen Yen; Rou-Shayn Chen; Shiaw-Pyng Wey; Chin-Song Lu
Journal:  J Neurol       Date:  2007-10-15       Impact factor: 4.849

8.  Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice.

Authors:  Tohru Kitada; Antonio Pisani; Douglas R Porter; Hiroo Yamaguchi; Anne Tscherter; Giuseppina Martella; Paola Bonsi; Chen Zhang; Emmanuel N Pothos; Jie Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-11       Impact factor: 11.205

9.  SARM1 and TRAF6 bind to and stabilize PINK1 on depolarized mitochondria.

Authors:  Hitoshi Murata; Masakiyo Sakaguchi; Ken Kataoka; Nam-Ho Huh
Journal:  Mol Biol Cell       Date:  2013-07-24       Impact factor: 4.138

Review 10.  SPECT molecular imaging in Parkinson's disease.

Authors:  Ling Wang; Qi Zhang; Huanbin Li; Hong Zhang
Journal:  J Biomed Biotechnol       Date:  2012-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.